BioMarin Pharmaceutical Inc. Files 8-K on Financials

Ticker: BMRN · Form: 8-K · Filed: May 1, 2025 · CIK: 1048477

Biomarin Pharmaceutical INC 8-K Filing Summary
FieldDetail
CompanyBiomarin Pharmaceutical INC (BMRN)
Form Type8-K
Filed DateMay 1, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

Related Tickers: BMRN

TL;DR

BioMarin dropped an 8-K on May 1st covering their financials - check it for the latest numbers.

AI Summary

BioMarin Pharmaceutical Inc. filed an 8-K on May 1, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. BioMarin Pharmaceutical Inc. is incorporated in Delaware and headquartered in Novato, California.

Why It Matters

This filing provides investors with updated information on BioMarin's financial health and operational results, which can influence investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on BioMarin Pharmaceutical Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 1, 2025.

In which state is BioMarin Pharmaceutical Inc. incorporated?

BioMarin Pharmaceutical Inc. is incorporated in Delaware.

What is the address of BioMarin's Principal Executive Offices?

The address of BioMarin's Principal Executive Offices is 770 Lindaro Street, San Rafael, California 94901.

What is the company's telephone number?

The company's telephone number is (415) 506-6700.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 1, 2025 regarding BIOMARIN PHARMACEUTICAL INC (BMRN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing